Global Genital Herpes Pipeline Accelerates with 18+ Companies Advancing Novel Treatments, Reports DelveInsight

According to DelveInsight's analysis, the global Genital Herpes pipeline features more than 18 key pharmaceutical companies actively developing over 20 therapeutic candidates. The report evaluates ongoing clinical trials, therapy landscapes, mechanisms of action, routes of administration, and key developmental milestones shaping this space.

DelveInsight's "Genital Herpes Pipeline Insight, 2025" report delivers an in-depth review of the current clinical development landscape and future growth outlook of the Genital Herpes market. The study offers comprehensive commercial and clinical evaluations of pipeline candidates spanning preclinical to marketed stages. It includes detailed drug profiles covering mechanisms of action, study status, regulatory milestones (including NDAs, where applicable), technology platforms, collaborations, M&A activities, funding rounds, designations, and other product-level developments.

Request for sample report - https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Genital Herpes Pipeline Report
• Numerous global companies are actively advancing next-generation therapies for Genital Herpes, achieving significant progress in recent years.
• April 2025: Assembly Biosciences presented early clinical and preclinical findings for ABI-5366, a novel helicase-primase inhibitor (HPI) targeting HSV-1 and HSV-2, at the 35th ESCMID Global Conference in Vienna. Designed for weekly or monthly oral dosing, ABI-5366 demonstrates strong tissue penetration, favorable PK properties, and nanomolar-level potency. It holds potential to address adherence and durability limitations associated with nucleoside analogs and may reshape recurrent genital herpes (RGH) management.
• Leading companies developing Genital Herpes therapies include Moderna Therapeutics, Vaxxit, Nanoviricides, BioNTech, GlaxoSmithKline, United BioPharma, Heidelberg ImmunoTherapeutics, AiCuris, and others.
• Key emerging candidates across clinical stages include attenuated HSV-1/2 vaccines, topical creams, BNT163, GSK3943104A, UB-621, HDIT101, Pritelivir, and more-expected to significantly influence the market outlook.
• May 2024: Wisp expanded its partnership with TBD Health, enabling broader access to STI/STD testing kits, PrEP prescriptions, UTI treatments, and other sexual health services via its platform.

Genital Herpes: Overview
Genital herpes is a widespread sexually transmitted infection caused primarily by HSV-2, though HSV-1 is increasingly implicated. It manifests as painful blisters, genital sores, itching, and dysuria. The virus establishes lifelong latency in nerve cells, leading to recurrent outbreaks. While there is no cure, antiviral agents help reduce symptom severity, frequency of recurrences, and transmission risk.

Get a Free Sample PDF Report to know more about Genital Herpes Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Genital Herpes Drug Candidates in Development
Notable pipeline therapies include:
• mRNA-1608 - Moderna Therapeutics
• Attenuated HSV-1/2 vaccine - Vaxxit
• HSV "Genital lesions" topical cream/lotion - Nanoviricides
• BNT163 - BioNTech
• GSK3943104A - GlaxoSmithKline
• UB-621 - United BioPharma
• HDIT101 - Heidelberg ImmunoTherapeutics
• Pritelivir - AiCuris

Genital Herpes Route of Administration (ROA) Assessment
The report categorizes pipeline therapies by ROA:
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Genital Herpes Drugs Molecule Type Classification
Genital Herpes therapeutics under development span a diverse set of molecule types, including:
• Monoclonal antibodies
• Peptides
• Polymers
• Small molecules
• Gene therapies

Genital Herpes Therapeutic Assessment Overview
The Genital Herpes pipeline is analyzed based on:
• Product type
• Development stage
• Route of administration
• Molecule type
• Stage-product and stage-ROA correlations

DelveInsight's Genital Herpes Clinical Trial Assessment report covers more than 20 candidates across:
• Phase III (late-stage) products
• Phase II (mid-stage) products
• Phase I (early-stage) products
• Preclinical & discovery stage programs
• Discontinued/inactive candidates

Further Genital Herpes product details are provided in the report. Download the Genital Herpes pipeline report to learn more about the emerging Genital Herpes therapies at:
https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Companies in the Genital Herpes Therapeutics Space
Major Genital Herpes Companies include AiCuris, United BioPharma, Heidelberg ImmunoTherapeutics, Genocea Biosciences, Agenus, Fresh Tracks Therapeutics, Sanofi, GlaxoSmithKline, and others.

Genital Herpes Pipeline Analysis Highlights
The report provides insights into:
• Company-wise therapeutic portfolios for Genital Herpes
• Segmentation of candidates by development stage (early, mid, late)
• Active and inactive projects within targeted therapeutic programs
• Mechanisms of action, targets, ROA, and molecule types
• Collaborative trends, licensing deals, and financing activities shaping market evolution
• Data compiled from proprietary databases, clinical trial registries, institutional websites, SEC filings, investor presentations, conferences, and authoritative third-party sources

Genital Herpes Market Drivers
• Growing awareness of genital herpes and increasing availability of sensitive nucleic acid amplification tests are driving market growth.

Genital Herpes Market Barriers
• Limited diagnostic accessibility, insufficient R&D investment, pricing pressures, regulatory constraints, and lack of novel HSV-2 suppression strategies continue to challenge market expansion.

Download Sample PDF Report to know more about Genital Herpes drugs and therapies-
https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Genital Herpes Pipeline Report
• Coverage: Global
• Key Companies: Moderna, Vaxxit, Nanoviricides, BioNTech, GSK, United BioPharma, Heidelberg ImmunoTherapeutics, AiCuris, and others
• Key Emerging Therapies: HSV vaccines, topical antivirals, BNT163, GSK3943104A, UB-621, HDIT101, Pritelivir, etc.
• Assessment Areas: Marketed and emerging therapies, market dynamics, product advancement timelines, and comprehensive pipeline analytics.

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.